Leaderboard

En | De
Sie sind hier: Onkologie » Urologische Tumoren 10. Juli 2026
Suchen
medline.ch
Urologische Tumoren
Erweiterte Suche
Dermatologie
Endokrinologie
Ernährung
Gastroenterologie
Gynäkologie
Hämatologie
Infektiologie
Kardiovaskuläre Erkrankungen
Muskuloskelettale Erkrankungen
Neurologie
Onkologie
Bewegungsapparat
Blut
Endokrine Organe
Gynäkologische Tumoren
Haut
Magen-Darm
ORL
Respirationstrakt
Urologische Tumoren
ZNS
Ophthalmologie
ORL
Pädiatrie
Psychiatrie
Respirationstrakt
Sportmedizin
Urologie-Nephrologie
Schrift: Schrift grösser Schrift kleiner

Rect Top
   Seite 1 von 8994  vorhergehende Seite nächste Seite
   
   Artikel 1 - 20 / 179871  
   
Triplet therapy with darolutamide and docetaxel for metastatic castration-sensitive prostate cancer: a multicenter real-world study.
Jpn J Clin Oncol
Tsuru I, Taguchi S, Tanaka R, Kawai T, Kaneko T, Nakamura Y, Miyauchi Y, Hoshina H, Obinata D, Koshiba M, Shiozaki M, Takahashi J, Kano M, Naito A, Suda S, Noda M, Sugiyama N, Tanaka T, Uemura Y, Miyakawa J, Kamei J, Kakutani S, Niimi A, Yamada Y, Sato Y, Yamada Y, Nishimatsu H, Murata T, Takahashi S, Takada T, Akiyama Y, Takahashi S, Fujimura T, Fukuhara H, Nakagawa T, Kume H.
PMID: 42424546 [PubMed - as supplied by publisher]


Platinum-based chemotherapy in metastatic castration-resistant prostate cancer: a narrative review and dual stratification framework based on HRR genotype and aggressive-variant/neuroendocrine phenotype.
Int Urol Nephrol
Chen H, Wang Y, Ding Y, Qu M, Gao X.
PMID: 42423955 [PubMed - as supplied by publisher]


Outcomes of Neoadjuvant Radiotherapy Followed by Robotic Radical Prostatectomy in High-Risk Locally Advanced Prostate Cancer: A Prospective Pilot Study.
Ann Surg Oncol
Tseng CS, Chang CK, Li HJ, Liu YT, Huang SW, Huang CY, Cheng JC.
PMID: 42423939 [PubMed - as supplied by publisher]


Association Between Psoriasis and Prostate Cancer Risk in Men: A Retrospective Cohort Study.
J Epidemiol Glob Health
Lai SW, Liao KF.
PMID: 42423818 [PubMed - as supplied by publisher]


[Geriatric assessments and their practical application in uro-oncology : How do we decide on prostate cancer treatment in an age-appropriate way?].
Urologie
Fiebig C, Manseck A, Stein J, Piotrowski A, Fröhner M, Umbehr M, Butea-Bocu M, Wiedemann A.
PMID: 42423720 [PubMed - as supplied by publisher]


Treatment of High-Risk Biochemically Recurrent Prostate Cancer with Enzalutamide in Combination with Leuprolide: Secondary End Points from the EMBARK Trial: Erratum.
J Urol
Shore ND, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Sridharan S, Brasso K, Woo HH, Caamaño AG, Saranchuk JW, Nordquist LT, Ferreira U, Tang Y, Rosbrook B, Haas GP, Rosales M, Zohren F, Tarazi J, Freedland SJ.
PMID: 42423152 [PubMed - in process]


A retrospective observational analysis of the global burden of smoking-attributable prostate, bladder, and kidney cancers among adults aged 40 years and older: Based on the global burden of disease study 2021 with projections to 2045.
Sci Prog
Chen N, Cai J, Feng J, He Y, Xu D.
PMID: 42423065 [PubMed - indexed for MEDLINE]


Overview of clear cell renal cell carcinoma: from mechanisms to clinical.
Front Med (Lausanne)
Yang H, Zhang X, Ji Q, Sheng X.
PMID: 42422841 [PubMed]


Late Renal Cell Carcinoma Metastasis Mimicking an Arteriovenous Malformation in the Parotid and Masseter Region: A Diagnostic Pitfall.
Cureus
Huerta Diaz LA, Lopez Alanis BA, Ortiz Villeda FE, Treviño Lozano MA, Muñoz-Maldonado GE.
PMID: 42422606 [PubMed]


Magnetic Resonance Imaging-based Prostate Cancer Diagnosis Using Principal Component Analysis and Machine Learning Algorithms.
J Med Phys
Samta N, Sureka CS, Sarasanandarajah S, Jeevanram RK.
PMID: 42422134 [PubMed]


Navigating Recurrence in Clear Cell Renal Cell Carcinoma after Adjuvant Immunotherapy.
J Kidney Cancer VHL
Sunny G, Ravichandran S, Patnaik A, Yadav R.
PMID: 42422057 [PubMed]


Evolution of the prostate cancer diagnostic paradigm: integrated evidence and clinical pathways from targeted biopsy to biopsy-free strategy.
Front Oncol
Liu Z, Wu J, Lu Q, Li Y, Yang Y.
PMID: 42421680 [PubMed]


Keratin 17 immunocytochemistry in urine cytology for urothelial carcinoma detection: Diagnostic performance and interobserver agreement in a prospective real-world cohort.
Cancer Cytopathol
Barth G, Koch S, Ecke TH.
PMID: 42421607 [PubMed - indexed for MEDLINE]


Diabetes Is an Independent Risk Factor for Radiation-Induced Hematuria After Robotic Stereotactic Body Radiotherapy for Prostate Cancer.
Int J Urol
Elting L, Almohtasib J, Francisco IFS, Pérez-Londoño A, Al-Faouri R, Kaplan I, Aronovitz J, Mehta P, Gershman B, Olumi AF, Aghdam N.
PMID: 42421489 [PubMed - indexed for MEDLINE]


Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of '-mabs'?
J Pathol
Schepisi G, Torresan I, Giunta EF, Bleve S, Brighi N, Tassinari E, Zanuccoli S, Cursano MC, Lolli C.
PMID: 42420213 [PubMed - as supplied by publisher]


Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making.
Eur Urol Oncol
Thibault C, Blons H, Allory Y, Harba A, Roumiguié M, Seisen T, Marcq G, Bajeot AS, Leon P, Masson-Lecomte A, Pradère B, Xylinas E, Prost D, Gabriel PE, Laurent-Puig P, Rouprêt M, Audenet F, Cancer Committee of The French Association of Urology (CC-AFU).
PMID: 42420157 [PubMed - as supplied by publisher]


MRI-based Response Assessment of Neoadjuvant Systemic Immunotherapy in Muscle-invasive Bladder Cancer: An Analysis of Inter-radiologist Variability and Diagnostic Accuracy in three Prospective Clinical Trials.
Eur Urol Oncol
Greidanus J, van Dijk-de Haan MC, Messina A, Calareso G, Bruining A, Westerink B, Dehghanpour A, Tissier R, van Dorp J, Stockem CF, Pipinikas C, Mertens LS, van der Poel HG, Beets-Tan RGH, van Rhijn BWG, Giannatempo P, van der Heijden MS, Trebeschi S, Boellaard TN.
PMID: 42420156 [PubMed - as supplied by publisher]


Development and acceptability of gist-based decision aids for prostate and breast cancer screening: a two-phase qualitative interview study in an online setting.
BMJ Open
Nalavenkata S, Bergengren O, Lynch K, Emard N, Austria M, Martin S, Ogbennaya G, Dualeh K, Stevanovic K, Patel MI, Gonsky J, Vickers A, Fagerlin A, Hamilton JG, Hay JL, Carlsson S.
PMID: 42419884 [PubMed - indexed for MEDLINE]


(Cost-)effectiveness of focal therapy versus radical therapy (standard of care) in the treatment of men with intermediate-risk prostate cancer: study protocol for the ENFORCE focal randomised controlled trial.
BMJ Open
Te Molder LPW, Sedelaar JPM, Bomers JGR, Boomsma MF, de Haan TD, van Melick HHE, Meijerink MR, Beerlage HP, van Aubel O, Collette ER, Grutters JPC, Hannink G, Rovers MM, Fütterer JJ, ENFORCE Focal consortium.
PMID: 42419881 [PubMed - indexed for MEDLINE]


Advances in systemic therapies for advanced prostate cancer.
BMJ
Childs DS, Hahn AW, Ravi P, Orme JJ.
PMID: 42419784 [PubMed - indexed for MEDLINE]


   
   Artikel 1 - 20 / 179871    Seite 1 von 8994  vorhergehende Seite nächste Seite

 
Rect Bottom
Adserver Footer
 

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

 

Übersetzungsproblem?

mehr >>

  Zeitfenster  
   

Sky right 1